urticaria: A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
134 |
4. Check minimum number of eventsNone |
134 |
5. Include endpointsNone |
134 |
6. Filter based on genotype QC (FinnGen only) |
122 |
Control definitions (FinnGen only)
- Control exclude
- L12_URTICARIAERYTHEMA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L50
- Name in latin
- Urticaria ex contactu
Similar endpoints
↥List of similar endpoints to
Contact urticaria
based on the number of shared cases.
Similar with more cases:
- Urticaria
- Urticaria and erythema
- Diseases of the skin and subcutaneous tissue
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 756 | 481 | 272 |
| Only index persons | 681 | 448 | 233 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 33.99 | 36.01 | 30.25 |
| Only index persons | 36.48 | 36.75 | 35.95 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 122 | 92 | 30 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.01 |
| Median age at first event (years) | 43.30 | 41.46 | 48.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 126
- Matched controls
- 1260
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L50.60
ICD-10 Finland
Allergic contact urticaria
+∞
82.6
70
*
L50.6
ICD-10 Finland
Contact urticaria
+∞
37.4
34
*
L50.69
ICD-10 Finland
Other (non-immunological) contact urticaria
+∞
27.0
25
*
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
7.9
23.7
40
70
XQ800
NOMESCO Finland
Prick test
8.1
17.8
27
41
L50.8
ICD-10 Finland
Other urticaria
+∞
17.1
16
*
R06AE07
ATC
cetirizine; oral
3.8
11.7
83
425
L50.9
ICD-10 Finland
Urticaria, unspecified
17.2
11.7
18
12
L50.3
ICD-10 Finland
Dermatographic urticaria
131.5
11.6
12
*
L50.0
ICD-10 Finland
Allergic urticaria
28.7
10.0
13
5
R06AX27
ATC
desloratadine; oral
3.3
9.7
61
281
R03DC03
ATC
montelukast; oral
3.6
8.7
36
127
M54.4
ICD-10 Finland
Lumbago with sciatica
3.5
8.6
38
140
H02AB06
ATC
prednisolone; systemic
3.0
8.3
76
424
XQ802
NOMESCO Finland
Epicutan test
8.7
8.2
17
22
T78.4
ICD-10 Finland
Allergy, unspecified
6.6
7.2
18
31
C01CA24
ATC
epinephrine; parenteral
4.5
6.9
18
45
R06AX13
ATC
loratadine; oral
3.2
6.7
31
116
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.9
6.7
39
167
H02AB04
ATC
methylprednisolone; systemic
3.4
6.5
26
89
N02AX02
ATC
tramadol; systemic, rectal
2.6
6.4
61
334
R06AE09
ATC
levocetirizine; oral
3.2
6.4
30
113
R06AX22
ATC
ebastine; oral
3.0
6.2
33
134
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
94
648
2.77
5.97
10.3
10.1
4.24
3.99
e9/l
0.56
78
564
17
37
5.14
5.74
1.1
1.1
6.52
0.88
u/ml
0.58
11
24
60
358
2.29
4.92
3.4
3.4
—
—
—
0
0
35
172
2.43
4.40
3.0
2.8
1.25
1.03
e6/l
0.12
17
88
15
50
3.27
3.83
1.6
1.4
—
—
—
0
0
101
791
2.40
3.82
9.3
7.9
70.58
77.13
u/l
1.63
96
749
16
56
3.13
3.79
1.4
1.5
—
—
—
0
0
71
503
1.94
3.29
5.8
6.0
1.21
1.21
mmol/l
0.37
62
438
9
20
4.76
3.18
1.2
1.1
—
—
—
0
0
9
20
4.76
3.18
1.2
1.1
—
—
—
0
0
7
12
6.10
3.06
1.3
1.2
—
—
—
0
0
14
52
2.90
3.00
1.9
2.8
5.42
6.47
ug/l
0.13
14
47
46
289
1.93
2.99
3.6
3.1
0.21
0.21
e6/l
0.01
32
210
13
47
2.97
2.91
1.8
1.5
—
—
—
0
0
30
167
2.05
2.72
2.9
2.8
0.82
0.81
mmol/l
0.14
30
161
106
891
2.19
2.70
4.5
4.7
14.48
14.51
pmol/l
0.04
99
833
12
44
2.91
2.63
1.3
1.3
—
—
—
0
0
43
275
1.86
2.60
6.1
3.4
1.01
1.02
kg/l
0.59
25
172
6
11
5.66
2.57
1.0
1.6
—
—
—
0
0
120
1091
3.10
2.52
18.8
14.0
23.89
20.52
mg/l
0.57
104
874
116
1022
2.70
2.48
4.6
4.4
5.58
5.77
mmol/l
1.50
109
958
38
238
1.85
2.43
1.9
1.7
0.53
0.79
mg/l
2.09
28
185
38
242
1.82
2.30
1.4
1.4
21.00
22.56
iu/ml
—
10
72
34
212
1.83
2.19
1.4
1.3
19.43
10.38
u/ml
0.21
16
85
12
49
2.60
2.18
1.2
1.1
—
8.72
—
0
5
8
26
3.21
2.05
1.6
1.3
—
—
—
0
0
22
122
1.97
2.00
8.0
7.5
104.32
104.40
mmol/l
0.03
22
122
27
161
1.86
1.99
3.3
3.0
1.40
3.20
e6/l
—
10
78
12
52
2.45
1.94
1.2
1.3
—
—
—
0
0
37
246
1.71
1.90
3.4
3.2
2077.80
1092.98
ng/l
0.36
30
205
6
17
3.65
1.86
1.5
1.2
—
—
—
0
0
16
81
2.12
1.84
1.6
1.4
—
—
—
0
0
5
12
4.29
1.84
1.0
1.2
—
—
—
0
0
21
119
1.92
1.80
2.5
2.9
4.43
7.17
umol/l
0.88
21
105
7
24
3.03
1.75
1.0
1.0
—
—
—
0
0
5
13
3.96
1.73
1.2
1.4
—
—
—
0
0
49
359
1.60
1.71
3.4
3.5
66.22
50.28
ng/l
0.11
32
206
44
314
1.62
1.71
6.6
3.7
0.00
0.00
estimate
-0.00
11
116
26
162
1.76
1.66
1.7
1.8
—
—
—
0
0
14
72
2.06
1.56
1.9
2.3
84.00
80.77
ml/min/173m2
—
6
26
14
72
2.06
1.56
1.1
1.0
—
—
—
0
0
74
606
1.54
1.54
5.9
3.7
0.00
0.00
estimate
-0.00
14
126
28
183
1.68
1.52
4.3
3.7
97.89
152.65
ng/l
0.25
19
115
73
601
1.51
1.45
6.0
3.7
0.00
0.00
estimate
-0.00
12
125
74
611
1.51
1.45
6.1
3.8
0.20
0.00
estimate
0.48
15
119
109
984
1.80
1.44
4.9
5.7
36.87
38.08
mmol/mol
0.90
102
936
7
29
2.49
1.41
1.9
1.3
—
—
—
0
0
16
91
1.87
1.36
1.9
2.2
10994.14
5170.63
u/l
—
5
36
56
441
1.49
1.35
5.5
3.6
0.08
0.01
estimate
0.40
13
107
41
304
1.52
1.32
2.0
2.2
141.83
170.07
u/l
0.38
41
295
5
18
2.85
1.29
1.4
1.3
—
—
—
0
0
42
318
1.48
1.21
1.7
1.4
1.02
1.71
u/ml
0.52
14
91
8
38
2.18
1.21
1.1
1.4
—
—
—
0
0
10
50
2.09
1.20
1.5
1.6
—
—
—
0
0
19
121
1.67
1.13
1.6
1.7
—
—
—
0
0
9
47
1.98
1.05
1.0
1.4
—
9.90
—
0
11
19
125
1.61
1.01
1.6
1.7
—
—
—
0
0
7
37
1.94
0.95
1.1
1.2
—
—
—
0
0
7
37
1.94
0.95
1.1
1.2
—
—
—
0
0
6
27
2.28
0.95
1.3
1.6
—
—
—
0
0
113
1058
1.66
0.93
4.6
4.5
1.41
1.49
mmol/l
1.29
108
1002
6
29
2.12
0.90
1.2
1.1
—
1.78
—
0
5
41
326
1.38
0.88
3.0
1.9
—
—
—
0
0
6
32
1.92
0.83
1.7
1.4
3.93
3.89
g/l
—
6
32
6
32
1.92
0.83
1.7
1.4
4.53
4.47
g/l
—
6
32
6
32
1.92
0.83
1.0
1.3
—
—
—
0
0
6
32
1.92
0.83
1.7
1.4
7.88
7.70
g/l
—
6
32
6
33
1.86
0.80
2.2
2.3
—
—
—
0
0
6
33
1.86
0.80
2.0
2.1
—
—
—
0
0
15
100
1.57
0.77
8.8
6.7
—
—
—
0
0
114
1079
1.59
0.76
5.4
5.0
2.84
2.74
mmol/l
0.40
108
1023
5
24
2.13
0.75
1.8
2.6
—
—
—
0
0
22
161
1.44
0.75
2.5
2.1
—
—
—
0
0
5
25
2.04
0.73
1.2
1.2
—
—
—
0
0
34
271
1.35
0.71
1.6
1.5
—
—
—
0
0
107
1004
1.44
0.70
4.0
3.8
1.25
1.25
mmol/l
0.00
102
942
7
43
1.66
0.68
1.0
1.3
—
—
—
0
0
110
1039
1.46
0.68
16.5
12.9
92.28
89.33
ml/min/173m2
0.87
102
941
11
70
1.63
0.67
1.4
1.4
—
—
—
0
0
11
70
1.63
0.67
6.5
7.2
26.14
24.99
mmol/l
0.62
11
70
18
130
1.45
0.66
2.2
1.9
—
—
—
0
0
24
305
0.74
0.63
4.2
4.0
21.09
9.33
mg/mmol
0.30
18
193
8
51
1.61
0.62
1.0
1.1
1.51
1.59
g/l
—
8
51
8
51
1.61
0.62
1.0
1.1
0.97
0.84
g/l
—
8
51
33
268
1.31
0.61
2.2
2.2
—
—
—
0
0
28
227
1.30
0.53
2.3
2.3
—
—
—
0
0
30
246
1.29
0.52
2.4
2.4
—
—
—
0
0
92
860
1.26
0.50
4.5
3.7
—
—
—
0
0
5
32
1.59
0.42
1.2
1.5
—
—
—
0
0
5
32
1.59
0.42
2.0
2.7
23.56
24.31
mmol/l
—
5
32
5
33
1.54
0.42
2.2
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
5.1
—
19.59
—
0
15
8
61
1.33
0.40
1.4
1.5
—
—
—
0
0
66
611
1.17
0.34
3.5
3.1
94.16
73.60
ug/l
0.48
61
583
49
448
1.15
0.29
2.4
1.9
97.61
97.40
pmol/l
0.01
29
228
5
40
1.26
0.22
1.8
1.8
95.80
96.52
%
—
5
40
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.8
—
13.10
—
0
14
10
81
1.25
0.19
2.2
2.8
56.35
71.65
ng/l
—
10
74
7
58
1.22
0.18
2.0
2.1
2.81
3.21
mg/l
—
7
38
21
188
1.14
0.16
2.3
2.7
2.47
2.43
mmol/l
1.46
21
167
6
58
1.04
0.08
1.7
1.6
—
—
—
0
0
5
62
0.80
0.08
1.4
1.5
183.80
287.04
mu/l
—
5
57
32
335
0.94
0.07
3.4
3.3
0.00
0.00
estimate
-0.00
12
99
15
138
1.10
0.07
1.3
1.7
1282.07
920.27
mu/l
—
9
118
46
473
0.96
0.05
2.0
1.8
1.34
1.37
mmol/l
0.12
39
417
58
570
1.03
0.03
2.4
2.7
—
—
estimate
—
0
0
17
167
1.02
0.00
3.8
4.7
0.91
1.74
ug/l
4.27
17
152
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
1.50
—
0
6
0
6
0.00
-0.00
0.0
5.3
—
11.00
—
0
6
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
9
95
0.94
-0.00
3.1
3.2
—
—
—
0
0
6
69
0.86
-0.00
1.3
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
14.43
—
0
7
0
6
0.00
-0.00
0.0
5.3
—
4.43
—
0
6
0
5
0.00
-0.00
0.0
1.6
—
13.20
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
12.44
—
0
9
0
5
0.00
-0.00
0.0
1.4
—
55.60
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
10.32
—
0
6
5
52
0.96
-0.00
1.4
1.5
44.06
53.00
ug/l
—
5
52
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
7
71
0.99
-0.00
1.3
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
9.60
—
0
5
0
7
0.00
-0.00
0.0
2.1
—
104.00
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_URTIGA_CONTACT and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have L12_URTIGA_CONTACT.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: L12_URTIGA_CONTACT – Contact urticaria
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data